ライフサイエンスコーパス: severe hepatitis

1 ion occurs with high frequency and can cause severe hepatitis.

2 of staining in many cells, concomitant with severe hepatitis.

3 d 37% of patients with genotype 2a or 2b had severe hepatitis.

4 al in those with immune-mediated features or severe hepatitis.

5 patitis (F <or= 2/6, NI <or= 3/18), moderate/severe hepatitis (3 <or= F < 6 or NI >or= 4/18), and cir

6 were abnormal serum potassium (32/97 [33%]), severe hepatitis (54/92 [59%]), and raised C-reactive pr

7 rwent liver biopsy, only 13% had evidence of severe hepatitis (8%) or cirrhosis (5%), despite a durat

8 at higher risk of infection with HAV and of severe hepatitis A disease outcomes compared with those

9 k for infection with HAV and higher risk for severe hepatitis A disease outcomes compared with those

10 We assessed risk factors for severe hepatitis A disease outcomes, including hospitali

11 Severe hepatitis A infection is an infrequent but well-r

12 deficient in inhibitory FcgammaRIIb had more severe hepatitis and accelerated mortality.

13 itonavir were reported to be associated with severe hepatitis and acute liver failure.

14 stingly, ILC2 depletion correlated with less severe hepatitis and reduced accumulation of eosinophils

15 these entities, mice experience increasingly severe hepatitis and tissue necrosis and die within a fe

16 VTTs in control, mild hepatitis, moderate or severe hepatitis, and cirrhosis groups were 38.3 seconds

17 levels of platelets, multifocal moderate to severe hepatitis, and perivascular edema.

18 patients had mild hepatitis; 18, moderate or severe hepatitis; and 10, cirrhosis.

19 post ConA injection, Wt mice presented with severe hepatitis as assessed by increased liver transfer

20 antagonist flutamide had significantly less severe hepatitis as determined by histologic activity in

21 infected with MHV-CXCL10 were protected from severe hepatitis as evidenced by reduced pathology and s

22 here have been no published reports of acute severe hepatitis associated with the use of OKT3 in non-

23 Until now, however, no cases of severe hepatitis attributed to zafirlukast have been rep

24 tation (OLTX) in patients retransplanted for severe hepatitis B virus (HBV) in the first allograft ha

25 fication of chemotherapy in patients who had severe hepatitis B virus flares.

26 opportunistic infection, graft rejection and severe hepatitis C virus recurrence).

27 Severe hepatitis cases in children are increasingly reco

28 9 (MHV-A59) produces meningoencephalitis and severe hepatitis during acute infection.

29 We describe here a case of acute severe hepatitis encountered during treatment of acute r

30 e liver failure, decompensated cirrhosis, or severe hepatitis flare) and in those with compensated ci

31 ivation in a cohort of patients experiencing severe hepatitis flares after stopping nucleot(s)ide ana

32 gue therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-tre

33 atic failure in a patient and, subsequently, severe hepatitis in a chimpanzee (CH1422), to analyze th

34 tomegalovirus strain v70 induces a rapid and severe hepatitis in immunocompetent mice that requires t

35 Cases of indeterminate severe hepatitis (iSH) may progress to indeterminate ped

36 l population, where they are associated with severe hepatitis, neurological disease, including mening

37 As of August 2022, clusters of acute severe hepatitis of unknown aetiology in children have b

38 BALB/c females developed more severe hepatitis (p<0.01) and produced more pro-inflamma

39 Castrated males developed more severe hepatitis than did intact males (p<0.001) and fem

40 e infected with HhG and HhNET developed less-severe hepatitis than male A/JCr mice infected with Hh3B

41 Patient 3 developed severe hepatitis that improved after treatment with cort

42 occur-though the occurrence of accompanying severe hepatitis was rare.

43 low RT-PCR cycle threshold (<20 cycles), and severe hepatitis were independently associated with mort

44 an be stratified into those with moderate to severe hepatitis, who merit imminent therapy, and those

45 in the liver, similar to MHV-2, and induced severe hepatitis with extensive hepatocellular necrosis.

46 etransplantation (2 = chronic rejection; 1 = severe hepatitis with panacinar necrosis, resembling ori

47 somewhat lower titer and induced moderate to severe hepatitis with zonal necrosis, similar to MHV-A59